SHANGHAI, January 12, 2025 – Argo Biopharmaceutical Co., Ltd. (“Argo Biopharma”), a clinical-stage biotechnology company focusing on developing a new generation of siRNA therapeutics, today announced that Dongxu Shu, PhD, Co-Founder and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16 at 7:30 a.m. PT at The Westin St. Francis San Francisco, Golden Gate Room, 32nd floor.

About Argo Biopharma

Founded in 2021, Argo Biopharma is a clinical-stage biotechnology company committed to developing a new generation of RNAi drugs to provide better treatment options for patients worldwide. Argo Biopharma has established a robust pipeline of RNAi drug candidates covering a wide range of indications including cardiometabolic diseases, viral infections, CNS and rare diseases. Currently, Argo Biopharma has five RNAi drug candidates in the clinical stage.

In a noteworthy milestone, Argo Biopharma achieved a strategic partnership with Novartis in January 2024 for $185 million in upfront payments and a total value exceeding $4 billion.